ClinicalTrials.gg
Active, not recruitingNCT07363473Updated Oct 30, 2026

JOURNEY LVAD: JOURNEY Left Ventricular Assist Device

An interventional study of J-Valve Transfemoral System in Aortic Valve Regurgitation, Aortic Valve Disease Mixed and Aortic Insufficiency, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC (part of Edwards Lifesciences) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now Active, not recruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences — 1 open to participants now, 4 under way, none of them phase 3. Aortic Valve Insufficiency · Edwards Lifesciences.

Planned enrollment
9th of 10
50 · median 164
Started
2026
the only one that year
No phase
10 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 11th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

1 of the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and effectiveness of the J-Valve Transfemoral Transcatheter Heart Valve System in patients on left ventricular assist device (LVAD) support with significant native aortic valve regurgitation (AR).

03

Conditions studied

  • Aortic Valve Regurgitation
  • Aortic Valve Disease Mixed
  • Aortic Insufficiency

Keywords

  • J-Valve Transfemoral System
  • Transcatheter Therapy
  • Transcatheter Aortic Valve Replacement
  • TAVR
  • Transfemoral
  • Left Ventricular Assist Device
  • LVAD
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult with durable left ventricular assist device (LVAD) support and AR (grade 4 or higher as assessed by core lab using TTE and adjunct TEE, if necessary) leading to LVAD dysfunction
  2. Symptomatic according to (NYHA) functional class II or higher
  3. High risk for surgery as judged by a multi-disciplinary heart team
  4. Suitable anatomy to accommodate the insertion, delivery, and deployment of the study devices (see anatomic exclusions below)
  5. Written and agreement to comply with all required follow-up visits at site

Exclusion criteria

Exclusion Criteria:

  1. Prior aortic valve replacement or repair
  2. Aortic valve stenosis > moderate as assessed by core lab
  3. Severe mitral valve or tricuspid valve regurgitation as assessed by core lab
  4. Severe mitral valve or tricuspid valve stenosis as assessed by core lab
  5. Active infection requiring current antibiotic therapy, including infective endocarditis
  6. Cardiac imaging evidence of cardiac mass, thrombus or vegetation
  7. Inability to tolerate or a condition precluding treatment with antithrombotic (antiplatelet, anticoagulant) therapy
  8. Renal insufficiency ( \<25 mL/min/1.73m2) or end stage renal disease requiring chronic dialysis
  9. Cirrhosis ( Class B or C)
  10. Leukopenia (WBC \<3000 cells/mcL), thrombocytopenia ( count \<50,000 cells/mcL), anemia ( \<9 g/dL), history of bleeding diathesis, coagulopathy, or hypercoagulable state (unless therapeutically stable)
  11. Known or to aspirin, heparin, bivalirudin, clopidogrel, Nitinol (Nickel, Titanium) or sensitivity to contrast media which cannot be adequately premedicated
  12. untreated coronary artery disease requiring revascularization or anticipated coronary revascularization procedure within 12 months post-index procedure
  13. Acute myocardial infarction within 30 days prior to index procedure
  14. PCI within 30 days prior to index procedure
  15. Carotid intervention within 6 weeks prior to index procedure or carotid artery disease requiring intervention
  16. Previous, or planned, other surgical or interventional procedures within 30 days before, during, or within 30 days after the index procedure
  17. Uncontrolled atrial fibrillation
  18. Severe right ventricular (RV) dysfunction as assessed by core lab or chronic inotrope support (>30 days)
  19. Severe pulmonary hypertension (systolic pulmonary artery pressure >80 mmHg measured by right heart catheterization)
  20. Severe (COPD) requiring chronic oral or requiring continuous home oxygen
  21. Stroke (cerebrovascular accident, CVA), (TIA) or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to index procedure
  22. Estimated of less than 12 months
  23. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements
  24. Participation in another study that has not reached its primary endpoint
  25. Considered to be part of a vulnerable population

Anatomic Exclusions:

  1. Ascending aortic diameter ≥5.5 cm as assessed by core lab
  2. Aortic annulus perimeter \<57 mm or >104 mm as assessed by core lab
  3. Inappropriate anatomy for femoral introduction and delivery of the study system
  4. Congenital aortic valve disease including unicuspid, bicuspid, or quadricuspid aortic valve anatomy as assessed by core lab
  5. Congenital univentricle or other condition that, in the opinion of the investigator and/or consulting physician, may constitute an unwarranted surgical risk
  6. Excessive aortic valve prolapse or leaflet deterioration that would preclude proper seating of the implant in the aortic annulus
  7. Abdominal/thoracic aortic aneurysm ≥5.0 cm as assessed by core lab
  8. Aorto-iliac disease requiring intervention to facilitate delivery of access sheath
  9. Excessive tortuosity of delivery system pathway, defined as severe tortuosity of multiple vessels including iliofemoral, thoracoabdominal aorta, aortic arch, and/or LV-aortic root angle >80°
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    J-Valve Transfemoral System

    Device: J-Valve Transfemoral System

Interventions

  • DeviceJ-Valve Transfemoral System

    Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    Freedom from moderate or severe total aortic regurgitation

    Time frame: 30 days

  2. Primary Safety Endpoint

    Freedom from all-cause mortality

    Time frame: 30 days

Secondary outcomes

  1. Valve embolization

    Valve embolization

    Time frame: During index procedure

  2. Need for second bioprosthetic valve

    Need for second bioprosthetic valve

    Time frame: During index procedure

  3. Change in cardiovascular-specific health status

    Change in cardiovascular-specific health status as measured by the Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score

    Time frame: 30 days compared with baseline

07

Study locations

2 sites
08

References and documents

Publications

  • Garcia S, Dowling R, Chung E, Egnaczyk GF, Stewart-Dehner TL, Answini GA, Paige D, Kereiakes DJ. J-Valve Transcatheter Treatment of Native Valve Aortic Regurgitation Associated With a Left Ventricular Assist Device. J Soc Cardiovasc Angiogr Interv. 2023 Jun 9;2(4):101044. doi: 10.1016/j.jscai.2023.101044. eCollection 2023 Jul-Aug. No abstract available. PubMed 39131634 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 18 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Apr 2026 → Sep 2026, primary completion Nov 2027 → Mar 2028 and completion Nov 2029 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 23, 2026
StartActual
Sep 22, 2026was Apr 2026
Primary completionEst.
Mar 2028was Nov 2027
CompletionEst.
Apr 2030was Nov 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 30, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Brigham and Women's Hospital · Boston, United States
  • Ascension St. Thomas West Hospital · Nashville, United States
Oct 30, 2026
Start date
Apr 2026→Sep 22, 2026 (actual)
Oct 30, 2026
Primary completion
Nov 2027→Mar 2028
Oct 30, 2026
Study completion
Nov 2029→Apr 2030
Oct 30, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedSevere right ventricular (RV) dysfunction as assessed by core lab or chronic inotrope support (>30 days)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Active, not recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Brigham and Women's Hospital · Boston, United States
    • Ascension St. Thomas West Hospital · Nashville, United States
    Start date Apr 2026→Sep 22, 2026 (now actual)
    Primary completion Nov 2027→Mar 2028
    Study completion Nov 2029→Apr 2030
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedSevere right ventricular (RV) dysfunction as assessed by core lab or chronic inotrope support (>30 days)
    + 2 other changes: contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07363473
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Sep 22, 2026
Primary completion
Mar 2028 (estimated)
Completion
Apr 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

Richard Cheng, MD
study chair · University of California, Los Angeles
Andrew Morse, MD
principal investigator · Ascension St. Thomas
Ulrich Jorde, MD
principal investigator · Montefiore Health System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion